Intellia Therapeutics

Business Services · Massachusetts, United States · 526 Employees

View Company Info for Free

About

Headquarters

40 Erie St Ste 130, Cambridge, Massachusetts, U...

Phone Number

(857) 285-6200

Website

www.intelliatx.com

Revenue

$46 Million

Stock Symbol

NTLA

Industry

Business Services General

Business Services

Most Recent Scoops

Sep 8 2024

Open Position

Aug 27 2024

Open Position

Intellia Therapeutics is currently seeking a Product Manager.

See all scoops

Highlights

$347.9M

Total Funding Amount

$150M

Most Recent Funding Amount

Number of Funding Rounds

View details

Who is Intellia Therapeutics

Intellia Therapeutics, headquartered in Cambridge, Massachusetts, and established in 2014, is a biotechnology company specializing in the developme nt of genome editing therapies to cure genetic diseases.Read more

Is this data correct?

View contact profiles from Intellia Therapeutics

Popular SearchesIntellia Therapeutics IncIntellia TherapeuticsIntelliaIntellia LtdIntellia LLCSIC Code 87,873NAICS Code 54,541Ticker NASDAQ: NTLAShow more

Intellia Therapeutics Org Chart

Shakked Halperin

Founder & Chief Executive Officer

Phone

Edward Dulac

Chief Financial Officer

Phone

Marika St. Amand

Senior Vice President, Chief Human Resources ...

Phone

Is Intellia Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Earning: See what the market has to say on Intellia Therapeutics recently announced quarterly report

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Intellia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic

Check if Intellia Therapeutics has recently received funding, and reach out quickly before it becomes old news!

Congratulate Masked Content for being promoted to Masked Content at Intellia Therapeutics

Funding: Get notified immidiatlly once Intellia Therapeutics has new funding data

Click to see if Intellia Therapeutics had a recent Job posting/layoffs

Check out if Intellia Therapeutics is spiking on competitors!

Product Launch: Get notified when Intellia Therapeutics launches new products

Website visits: Recent activity has been detected on your website

Recommended Actions

Reach out to Masked Content who joined Intellia Therapeutics as Masked Content

Find more new buyers

Similar Companies to Intellia Therapeutics

Analyze insights from companies similar to Intellia Therapeutics and make strategic comparisons based on performance, financial data, growth and unique benchmarks.

See more companies

View Email Formats for Intellia Therapeutics

Intellia Therapeutics financials insights

Gather financial insights about Intellia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

Graph showing recent funding, most recent acquisition, and main investor information for Intellia Therapeutics.

See All Financials Insights

Intellia Therapeutics Employee Growth Rate

Graph showing projected employee growth data for Intellia Therapeutics

View Intellia Therapeutics’s full employee growth data

Percentage of growth

1st year Mask

2nd year Mask

Intellia Therapeutics Tech Stack

A closer look at the technologies used by Intellia Therapeutics

PHP

See more technologies

Top Companies in United States

Most Recent Scoops

Sep 8 2024

Open Position

Aug 27 2024

Open Position

Aug 27 2024

Open Position

Intellia Therapeutics is currently seeking a Product Manager.

Aug 14 2024

Hiring Plans

Intellia Therapeutics has more open roles in Medicine than it has had at any time in the past 6 months.

Aug 14 2024

Hiring Plans

Intellia Therapeutics has more open roles in Medical Administration than it has had at any time in the past 6 months.

See more scoops

Intellia Therapeutics News & Media

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigational in vivo CRISPR-based gene edit
Sep 12, 2024
www.globenewswire.com
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants to five new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
Sep 3, 2024
www.globenewswire.com
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the second quarter ended June 30, 2024.
Aug 8, 2024
www.globenewswire.com
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET.
Aug 1, 2024
www.globenewswire.com
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. AAT
Jul 30, 2024
www.globenewswire.com

Frequently Asked Questions Regarding Intellia Therapeutics

Where is Intellia Therapeutics located?

Intellia Therapeutics's headquarters are located at 40 Erie St Ste 130, Cambridge, Massachusetts, United States

What is Intellia Therapeutics's phone number?

Intellia Therapeutics's phone number is (857) 285-6200

What is Intellia Therapeutics's stock symbol?

Intellia Therapeutics's stock symbol is NTLA

What is Intellia Therapeutics's official website?

Intellia Therapeutics's official website is www.intelliatx.com

What is Intellia Therapeutics's Revenue?

Intellia Therapeutics's revenue is $46 Million

What is Intellia Therapeutics's SIC code?

Intellia Therapeutics's SIC: 87,873

What is Intellia Therapeutics's NAICS code?

Intellia Therapeutics's NAICS: 54,541

How many employees does Intellia Therapeutics have?

Intellia Therapeutics has 526 employees

What industry does Intellia Therapeutics belong to?

Intellia Therapeutics is in the industry of: Business Services General, Business Services

What is Intellia Therapeutics competition?

Intellia Therapeutics top competitors include: Sangamo Therapeutics, Editas, Beam Therapeutics, bluebird bio

What companies has Intellia Therapeutics acquired?

Intellia Therapeutics has acquired the companies: Rewrite Therapeutics

What technology does Intellia Therapeutics use?

Some of the popular technologies that Intellia Therapeutics uses are: Angular 4, WordPress.org, Drupal, PHP

Who is the CEO of Intellia Therapeutics?

Intellia Therapeutics's CEO is Shakked Halperin

Who is the CFO of Intellia Therapeutics?

Intellia Therapeutics's CFO is Edward Dulac

How do I contact Intellia Therapeutics?

Intellia Therapeutics contact info: Phone number: (857) 285-6200 Website: www.intelliatx.com

What does Intellia Therapeutics do?

Intellia Therapeutics, headquartered in Cambridge, Massachusetts, and established in 2014, is a biotechnology company specializing in the development of genome editing therapies to cure genetic diseases.... Read More

What are Intellia Therapeutics social media links?

Intellia Therapeutics Linkedin page Intellia Therapeutics Twitter page Intellia Therapeutics Facebook page

How much funding has Intellia Therapeutics raised to date?

Intellia Therapeutics has raised $347.9 Million in 4 funding rounds

When was the last funding round for Intellia Therapeutics?

Intellia Therapeutics closed its last funding round on Nov 01, 2017 with the amount of $150 Million

Who invested in Intellia Therapeutics?

Intellia Therapeutics has 12 investors including Atlas Ventures, Foresite Capital, Novartis and Atlas Ventures.

Is Intellia Therapeutics a public company?

Yes, Intellia Therapeutics is a public company and is traded under the symbol NTLA

See more information about Intellia Therapeutics

Sell Smarter. Win Faster.

Level up your game to ZoomInfo Copilot, intuitive AI that turns your data and high-quality ZoomInfo data into an unfair advantage for your go-to-market teams.